Ross Klosterman
Long/short equity, special situations, small-cap, value

La Jolla Pharmaceuticals And The Aftermath Of The Phase II Data Readout

I had wanted to write this follow-up to my original article prior to La Jolla Pharmaceutical's (NASDAQ:LJPC) Phase II data readout, but given I have been slugging through a particularly brutal "busy season" at work, this did not happen. While some of what I have written below has been analyzed by others, I do think it prudent to provide some of my analysis and thought process over the past few weeks. I, of course, want to provide my opinion on some positive developments at the company since January, as well as my thoughts on the results of the GCS-100 Phase II data presented at the recent Roth Conference.

Reverse Split and Uplisting

Before I delve into data,...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details